Semaglutide Grey Market Risks and Quality

Semaglutide is a prescription-only medicine everywhere we cover: the US, the EU, the EEA, and the UK. It is sold under the brand names Ozempic, Wegovy, and Rybelsus, and every legitimate supply chain runs through a licensed pharmacy with a valid prescription. That has not stopped a parallel market from forming. Online vendors, social-media sellers, and unlicensed compounding operations sell products labelled as semaglutide to buyers who either cannot get a prescription or cannot afford the branded versions^[1]. This article covers what has gone wrong with those products, what regulators have found, and what you cannot verify on your own.

Counterfeit Ozempic in the regulated supply chain

The problem is not limited to back-alley websites. In June 2024 the WHO issued Medical Product Alert No. 2/2024 after falsified Ozempic batches were found inside regulated supply chains in Brazil, the United Kingdom, and the United States^[2]. Novo Nordisk confirmed that three batch numbers (LP6F832, NAR0074, and MP5E511) were not genuine. The WHO warned that using these products could result in "ineffective treatment of patients due to incorrect dosage, contamination with harmful substances, or use of unknown or substituted ingredients"^[2].

In the US, the FDA seized thousands of counterfeit Ozempic units. In April 2025 Novo Nordisk notified the FDA that several hundred additional counterfeit units had entered the US supply chain outside the authorised distribution network. The FDA found that the needles in these counterfeits could not be confirmed sterile, raising infection risk on top of the unknown contents of the pen itself^[3].

A 2026 analysis of the EudraVigilance pharmacovigilance database identified 234 individual case safety reports linked to suspected counterfeit semaglutide between 2018 and 2025. Of those, 89.3% were classified as serious. The most common adverse reactions were nausea, vomiting, and hypoglycaemia, with counterfeit products showing higher rates of hypoglycaemia and drug ineffectiveness than reports for genuine semaglutide^[4].

Compounded semaglutide: salt forms and dosing errors

During the FDA-declared semaglutide shortage (which has since been resolved), compounding pharmacies were permitted to prepare versions of the drug under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Some of those compounders used salt forms of semaglutide, including semaglutide sodium and semaglutide acetate. The FDA has stated that these are "different active ingredients than are used in the approved drugs" and that the agency "is not aware of any lawful basis for their use in compounding"^[1]. Whether these salts have the same pharmacological properties as the base form used in Ozempic and Wegovy remains unknown.

In July 2024 the FDA issued a compounding risk alert after receiving reports of adverse events, some requiring hospitalisation, tied to dosing errors with compounded injectable semaglutide. Patients were self-administering five to twenty times the intended dose. The errors stemmed from confusion between milligrams, millilitres, and "units" on non-standardised vial labels^[5]. Unlike the prefilled pens used for branded products, compounded vials require the patient to draw and measure each dose manually.

A 2026 study in the Annals of Pharmacotherapy catalogued 33 unique compounded semaglutide and tirzepatide products. Nearly half combined the active ingredient with add-ons such as cyanocobalamin, glycine, niacinamide, or ondansetron. The authors found "little justification" for these additions and noted that only 18% of products reported beyond-use dating and only 28% documented storage conditions^[6].

What happens when things go wrong

A 2026 case report in Cureus described an 18-year-old woman with no prior medical history who developed euglycaemic ketoacidosis after purchasing semaglutide online and self-administering escalating doses without medical supervision. She presented with a blood pH of 7.24 and elevated ketone levels despite normal blood glucose. The authors attributed the episode to a starvation state triggered by GLP-1-induced appetite suppression combined with gastrointestinal side effects and the absence of clinical monitoring^[7].

The FDA has also flagged fraudulent compounded products where the pharmacy names on the labels either do not exist or belong to licensed pharmacies that did not actually compound the product^[1]. In those cases, buyers have no way to trace the product back to a responsible manufacturer.

What a COA can and cannot tell you

A certificate of analysis (COA) from a grey-market vendor typically reports peptide purity by HPLC and molecular identity by mass spectrometry. That tells you whether the target molecule was present at the time of testing. It does not tell you whether the specific vial you received matches the tested batch, whether the product has degraded in transit or storage, or whether the COA itself is genuine. Grey-market COAs are generated by the manufacturer or a lab paid by the manufacturer, and there is no independent audit trail.

For semaglutide specifically, the COA also cannot confirm which salt form is in the vial. If the product contains semaglutide sodium rather than the base form, that difference would not necessarily appear on a standard COA panel, yet it changes the molecular weight and may change the effective dose. The same identity and purity concerns apply to other grey-market peptides, including BPC-157 and tirzepatide.

Harm reduction if you are considering grey-market semaglutide

This section is not an endorsement. Semaglutide is a prescription medicine for a reason: it requires dose titration, monitoring for gastrointestinal and metabolic side effects, and clinical judgement about whether it is appropriate for a given patient. If you are weighing the decision regardless, these are the questions worth asking.

Is the product coming from a licensed pharmacy that you can verify independently? Does the COA come from a named, independent third-party lab? Does the label specify the salt form and concentration? Are storage and expiry dates documented? Has anyone sent a sample from the same batch to a second lab for independent verification? If the answer to most of these is "no" or "I don't know," the product carries risks you cannot measure.

What we do not know

No published study has systematically tested a panel of grey-market semaglutide vials for identity, purity, contamination, and salt-form accuracy. The EudraVigilance data captures suspected counterfeits reported through the pharmacovigilance system, but it likely undercounts the true volume of counterfeit use^[4]. We do not know how many people are self-administering compounded or grey-market semaglutide without incident, and we do not know the real-world rate of serious adverse events outside the reporting systems.

If you are considering semaglutide for weight management or type-2 diabetes, that conversation belongs with a clinician who knows your medical history. For a full overview of semaglutide's clinical evidence and regulatory status across seven countries, see our semaglutide peptide page.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Semaglutide is a prescription-only medicine in every jurisdiction we cover. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.